TO COMPARE LEVELS OF C-REACTIVE PROTEIN (CRP) IN DRUG NAÏVE PATIENTS OF FIRST EPISODE OF SCHIZOPHRENIA, FIRST EPISODE OF BIPOLAR DISORDER (MANIA) AND HEALTHY CONTROLS

Dr. Ravi Kumar Gupta, Dr. Vikash Chandra Mishra, Dr. Gunjan Solanki

Abstract


Background:-. Schizophrenia, bipolar disorder are severe mental disorders with complex etiology and pathophysiology that are
far from being established. Infectious and inflammatory processes could potentially play an important role in the etiology and
pathogenesis of psychotic disorders. Results of studies are mostly conclusive and show raised level of CRP in these disorders.
However, fewer are studies comparing CRP levels in drug naive patients of these diagnostic groups.
AIM:- To compare levels of C-reactive protein (CRP) in drug naive patients of first episode of schizophrenia, first episode of
bipolar disorder (mania) and healthy controls.
Methodology A cross sectional hospital based Analytic type of Observational study was carried out between September 2017
and MAY 2018 Which included drug naive thirty cases each of first episode of schizophrenia(FES),first episode bipolar disorder
(mania) (FEBP)patients with thirty age and sex matched healthy controls. Blood samples of these groups were taken for
measurement of serum CRP levels.
Results:-
FES patients show significant raised serum C-reactive protein as compared to FEBP patients (mean diff. 5.90 and P <0.001) and
healthy controls (mean diff.8.48 and P <0.001), while FEBP patients also show significant raised serum C-reactive protein as
compared to healthy controls (mean diff. 2.58 and P <0.001).
CONCLUSION:- This present study adds to the growing body of literature indicating that schizophrenia is associated with
immune activation and elevated CRP.


Keywords


First Episode Of Schizophrenia ,first Episode Of Bipolar Disorder (mania),c- Reactive Protein.

Full Text:

PDF

References


Miller, B.J., Buckley, P., Seabolt, W., Mellor, A., Kirkpatrick, B., 2011. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 70 (7), 663–671.

Muller, N., Weidinger, E., Leitner, B., Schwarz, M.J., 2015. The role of inflammation in schizophrenia. Front. Neurosci. 9, 372

Marangoni, C., Hernandez, M., Faedda, G.L., 2016. The role of environmental exposures as risk factors for bipolar disorder: a systematic review of longitudinal studies. J. Affect. Disord. 193, 165–174.

Karpinski, P., Frydecka, D., Sasiadek, M.M., Misiak, B., 2016. Reduced number of peripheral natural killer cells in schizophrenia but not in bipolar disorder. Brain Behav. Immun. 54, 194–200.

Miller, B.J., Gassama, B., Sebastian, D., Buckley, P., Mellor, A., 2013. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 73 (10), 993–999

Laskaris, L.E., Di Biase, M.A., Everall, I., Chana, G., Christopoulos, A., Skafidas, E., Cropley, V.L., Pantelis, C., 2016. Microglial activation and progressive brain changes in schizophrenia. Br. J. Pharmacol. 173 (4), 666–680

Potvin, S., Stip, E., Sepehry, A.A., Gendron, A., Bah, R., Kouassi, E., 2008. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 63 (8), 801–808

Fernandes, B.S., Steiner, J., Bernstein, H.G., Dodd, S., Pasco, J.A., Dean, O.M., Nardin, P., Goncalves, C.A., Berk, M., 2016. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol. Psychiatry 21 (4), 554–564

FC:, Huang TL & Lin. High sensitivity C-reactive protein levels in patient with major depression. Prog in. Neuropharmacol and Biol Psychiatry, 31 (2007), 370-2.

Cunha AB1, Andreazza AC, Gomes FA, Frey BN, da Silveira LE, Gonçalves CA, Kapczinski F. Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. Eur Arch Psychiatry Clin Neurosci., 258, 5 (Aug 2008), 300-4.

Wadee AA, Kuschke RH, Wood LA, Berk M, Ichim L &. Maes M. Serological observations in patients suffering from acute manic episodes. Hum. Psychopharmacol , 17 (2002), 175-9.

Hope S1, Melle I, Aukrust P, Steen NE, Birkenaes AB, Lorentzen S, Agartz I, Ueland T, Andreassen OA. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord., 11, 7 (Nov 2009), 726-34.

Suvisaari J, Mantere O. Inflammation theories in psychotic disorders:a critical review.. Infect Disord Drug Targets , 13, 1 (2013), 59-70.

Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, de Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and metaanalysis. Schizophr Bull 2013; , 39, 2 (2013), 306-18.

Akanji AO, Ohaeri JU, Al-Shammri SA & Fatania HR. :Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Res., 169 (2009), 56-61.

.Müller N, Myint AM, Krause D, Weidinger E, Schwarz MJ. Antiinflammatory treatment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry , 5, 42 (2013), 146-53.

Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S,Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update.. Schizophr Bull, 40, 1 (2014), 181-91.


Refbacks

  • There are currently no refbacks.